ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 39.257
AS - Asia 17.543
EU - Europa 9.865
SA - Sud America 2.499
Continente sconosciuto - Info sul continente non disponibili 551
AF - Africa 433
OC - Oceania 51
Totale 70.199
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 38.139
SG - Singapore 5.135
CN - Cina 3.449
HK - Hong Kong 3.049
IT - Italia 2.145
VN - Vietnam 2.037
GB - Regno Unito 1.910
BR - Brasile 1.867
BD - Bangladesh 1.226
FI - Finlandia 1.136
SE - Svezia 1.064
KR - Corea 721
RU - Federazione Russa 721
DE - Germania 643
CA - Canada 514
FR - Francia 397
BG - Bulgaria 372
IN - India 371
PL - Polonia 363
AR - Argentina 245
TR - Turchia 241
ID - Indonesia 239
NL - Olanda 182
JP - Giappone 178
UA - Ucraina 176
MX - Messico 166
ZA - Sudafrica 149
IQ - Iraq 146
ES - Italia 131
AE - Emirati Arabi Uniti 127
AT - Austria 108
CO - Colombia 97
CR - Costa Rica 89
LT - Lituania 81
EC - Ecuador 80
IE - Irlanda 77
PK - Pakistan 77
EG - Egitto 60
CL - Cile 59
MA - Marocco 54
SA - Arabia Saudita 54
CZ - Repubblica Ceca 51
JM - Giamaica 51
UZ - Uzbekistan 51
PH - Filippine 49
VE - Venezuela 49
GT - Guatemala 44
HN - Honduras 44
IL - Israele 44
MY - Malesia 44
BE - Belgio 43
TT - Trinidad e Tobago 43
JO - Giordania 37
DZ - Algeria 36
PY - Paraguay 36
RO - Romania 36
AU - Australia 34
TN - Tunisia 32
KZ - Kazakistan 29
NP - Nepal 27
NI - Nicaragua 26
PE - Perù 26
SV - El Salvador 26
KE - Kenya 24
TH - Thailandia 24
AZ - Azerbaigian 23
PR - Porto Rico 23
AL - Albania 22
CH - Svizzera 21
ET - Etiopia 21
PT - Portogallo 20
UY - Uruguay 20
IR - Iran 19
BO - Bolivia 18
GR - Grecia 18
NO - Norvegia 17
DO - Repubblica Dominicana 16
GP - Guadalupe 15
KG - Kirghizistan 15
SC - Seychelles 15
A2 - ???statistics.table.value.countryCode.A2??? 14
BH - Bahrain 14
DK - Danimarca 14
EE - Estonia 14
TW - Taiwan 14
NZ - Nuova Zelanda 13
OM - Oman 13
RS - Serbia 13
CW - ???statistics.table.value.countryCode.CW??? 12
LB - Libano 12
MK - Macedonia 12
GE - Georgia 11
MD - Moldavia 11
QA - Qatar 11
BZ - Belize 10
HU - Ungheria 10
LV - Lettonia 10
BB - Barbados 9
KH - Cambogia 9
BS - Bahamas 8
Totale 69.498
Salva come PNG Salva come JPEG
Città #
Ashburn 4.821
Santa Clara 3.762
Singapore 3.284
Hong Kong 2.986
Fairfield 2.374
Chandler 2.081
San Jose 1.631
Council Bluffs 1.184
Helsinki 1.087
New York 1.074
London 999
Nyköping 857
Woodbridge 850
Houston 838
Los Angeles 793
Wilmington 763
Seattle 718
Hefei 706
Ho Chi Minh City 644
Cambridge 626
Beijing 619
The Dalles 594
Seoul 591
Chicago 556
Boardman 517
Hanoi 507
San Diego 480
Ann Arbor 477
Princeton 386
Sofia 359
Southend 344
Warsaw 342
North Bergen 318
Milan 317
Buffalo 293
Oakland 286
Sunnyvale 284
Piscataway 233
Moscow 223
Orem 222
Dallas 208
Salt Lake City 198
Shanghai 197
Modena 185
Jersey City 183
São Paulo 180
Jacksonville 168
Secaucus 168
Jakarta 156
Dearborn 152
Phoenix 148
Atlanta 143
Rome 140
Newark 132
Tokyo 130
Redondo Beach 115
Toronto 114
Da Nang 110
Istanbul 108
Clifton 104
Brooklyn 101
Denver 97
Porto Alegre 97
Frankfurt am Main 96
Saint Augustine 92
Lauterbourg 90
Chennai 89
San Francisco 89
Haiphong 87
Johannesburg 87
Bremen 86
Montreal 86
Bupyeong-gu 84
Bologna 80
Tampa 79
Washington 75
Naples 72
Dublin 68
San José 68
Vienna 68
Elk Grove Village 67
Munich 67
Philadelphia 66
Miami 64
Amsterdam 62
Charlotte 62
Columbus 62
Mexico City 61
Manchester 58
Norwalk 57
Rio de Janeiro 57
Boston 55
Stockholm 55
Augusta 54
Paris 54
Las Vegas 53
Nuremberg 53
Miano 52
Detroit 51
Viroflay 51
Totale 45.917
Salva come PNG Salva come JPEG
Nome #
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 1.299
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis 575
Non-alcoholic steatohepatitis and liver transplantation 540
Side Effects of Immunosuppressant Drugs After Liver Transplant 489
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 418
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 399
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 384
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 383
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 364
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 360
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 360
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 353
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 345
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 344
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 336
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 334
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 331
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 329
From current status to optimization of HCV treatment: Recommendations from an expert panel 314
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 310
Missed treatment in an Italian HBV infected patients cohort: HBV RER 309
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 308
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 307
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 301
Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool 300
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 293
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 286
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 286
Global multi-stakeholder endorsement of the MAFLD definition 285
Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension 282
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 282
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 279
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 277
Treatment of nonalcoholic steatohepatitis in adults: present and future 274
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 274
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B 270
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 269
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 268
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 268
Adaptive response in Hepatitis B virus infection 268
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 263
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 262
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 261
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 260
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 258
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study 257
Characteristics of hepatocellular carcinoma in Italy 256
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 251
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 250
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 249
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 249
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 248
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study 246
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 246
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 245
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 244
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 244
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 244
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 240
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): A randomised, double-blind, non-inferiority phase 3 trial 240
Alcohol and viral hepatitis: a mini-review 238
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 237
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 236
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 234
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 233
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 232
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 231
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 230
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 230
Clinical and serological profile of primary biliary cirrhosis in men 230
Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis 230
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 229
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 228
CD 133+ stem cells for the treatment of end stage liver disease 228
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 228
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 227
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 226
Gross pathologic types of hepatocellular carcinoma in Italy. 225
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 225
Detection of HCV antigens in liver graft: Relevance to the management of recurrent post-liver transplant hepatitis C 223
Familial intrahepatic cholestasis: New and wide perspectives 222
Comparing and combining gamma-hydroxybutiric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study 222
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 222
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 221
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 221
Update on Alcohol and Viral Hepatitis 220
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 219
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 218
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 217
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 216
Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy 215
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 214
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 214
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 213
Chronic hepatitis B: Are we close to a cure? 213
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 213
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 209
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 209
Lipidomic profiling of MASLD: identifying lipid biomarkers for detection and stratification of disease severity 207
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B 206
Totale 28.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 339.982
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 339.982
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.936 0 0 0 0 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202627.515 1.254 771 1.937 2.630 3.300 2.823 3.041 1.658 2.592 2.540 2.539 2.430
2026/202710.078 1.871 2.414 2.057 3.171 565 0 0 0 0 0 0 0
Totale 70.199